2014
DOI: 10.1007/s10354-014-0271-3
|View full text |Cite
|
Sign up to set email alerts
|

Pathways of Tumor development and progression in Drug-induced Nonmelanoma Skin Cancer: a New Hope or the Next Great Confusion?

Abstract: The factors that lead to the clinical manifestation of the nonmelanocytic skin tumors are different. Ultraviolet radiation, infections with human papillomaviruses, and inherited or iatrogenic-induced immunosuppression (in cases of autoimmune diseases and organ transplant recipients) are considered to be some of the most important generators and/or costimulating factors supporting the appearance of "de-novo" mutations and obstruct, in one or another way, the cell cycle arrest, the programmed cell death (apoptos… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
16
0

Year Published

2014
2014
2014
2014

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(16 citation statements)
references
References 62 publications
0
16
0
Order By: Relevance
“…There is an increased risk of melanoma and also non-melanoma skin cancer in patients treated with TNF-alpha inhibitors (3,11). The risk for nonmelanoma skin cancer is increased 2 to 3 fold by TNF-alpha inhibitors (11).…”
Section: Case Reportmentioning
confidence: 99%
See 4 more Smart Citations
“…There is an increased risk of melanoma and also non-melanoma skin cancer in patients treated with TNF-alpha inhibitors (3,11). The risk for nonmelanoma skin cancer is increased 2 to 3 fold by TNF-alpha inhibitors (11).…”
Section: Case Reportmentioning
confidence: 99%
“…The mitochondrial or intrinsic and the death ligand mediated, extrinsic apoptotic pathway seems to be the most important pathways for the integrity of genome and the elimination of the neoplastic cells (3,13). Death receptors 4 and 5, known also as DR4 and DR5 are cell surface receptors that could be activated by their tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL), that could trigger apoptosis in most cancer cells in BCC and SCC, but not in normal cells (14).…”
Section: Case Reportmentioning
confidence: 99%
See 3 more Smart Citations